All publications - IKF – Institut für klinische Forschung

Salvage Autologous Transplant in Relapsed Multiple Myeloma: Long-Term Follow-Up of the Phase 3 GMMG ReLApsE Trial

Authors: Baertsch MA, Schlenzka J, Hielscher T, Raab MS, Sauer S, Merz M, Mai EK, Müller-Tidow C, Luntz S, Jauch A, Brossart P, Goerner M, Klein S, Glass B, Reimer P, Graeven U, Fenk R, Haenel M, von Metzler I, Lindemann HW, Scheid C, Blau IW, Salwender HJ, Noppeney R, Besemer B, Weisel KC, Goldschmidt H.

Journal: Blood . 2025 Jan 14:blood.2024027342.

Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma

Authors: Grieb N, Oeser A, Ferle M, Hanke F, Flossdorf S, Sauer S, Goldschmidt H, Müller-Tidow C, Salwender HJ, Fenk R, Engelhardt M, Zeiser R, Vucinic V, Franke GN, Blau IW, Teschner D, Einsele H, Kimmich C, Kull M, Besemer B, Gagelmann N, Kröger N, Neumuth T, Platzbecker U, Merz M; German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST).

Journal: Bone Marrow Transplant . 2024 Dec 5.

Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries

Authors: Seckinger A, Salwender H, Martin H, Scheid C, Hielscher T, Bertsch U, Hummel M, Jauch A, Knauf W, Emde-Rajaratnam M, Beck S, Neben K, Dührig J, Lindemann W, Schmidt-Wolf IGH, Hänel M, Blau IW, Weisel K, Weinhold N, Raab MS, Goldschmidt H, Choon-Quinones M, Hose D.

Journal: Int J Mol Sci . 2024 Jun 11;25(12):6431.

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial

Authors: Mai E, Bertsch U, Pozek E, Fenk R, Besemer B, Hanoun C, Schroers R, von Metzler I, Hänel M, Mann C, Leypoldt L, Heilmeier B, Huhn S, Vogel S, Hundemer M, Scheid C, Blau I, Luntz S, Weinhold N, Tichy D, Holderried T, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Shumilov E, Knauf W, Michel C, Geer T, Riesenberg H, Lutz C, Raab M, Benner A, Hoffmann M, Weisel K, Salwender H, Goldschmidt H.

Journal: J Clin Oncol . 2024 Dec 9:JCO2402266.

Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation

Authors: Hummel M, Hielscher T, Emde-Rajaratnam M, Salwender H, Beck S, Scheid C, Bertsch U, Goldschmidt H, Jauch A, Moreaux J, Seckinger A, Hose D.

Journal: JCO Precis Oncol. 2024 Jul;8:e2300613.

Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma

Authors: Leypoldt LB, Tichy D, Besemer B, Hanel M, Raab MS, Mann C, Munder M, Reinhardt HC, Nogai A, Gorner M, Ko YD, de Wit M, Salwender H, Scheid C, Graeven U, Peceny R, Staib P, Dieing A, Einsele H, Jauch A, Hundemer M, Zago M, Pozek E, Benner A, Bokemeyer C, Goldschmidt H, Weisel KC.

Journal: Future Oncol. 2024 Dec;20(39):3193-3207.